evidenceFinder is intended for health care professionals only.

The information found within this portal1 includes:

  • Novo Nordisk sponsored Health Economics & Outcomes Research (including real world studies) in a US population2 for Victoza® (liraglutide injection) 1.2 mg or 1.8 mg; Ozempic® (semaglutide) injection 0.5 mg or 1 mg; Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL; Tresiba® (insulin degludec injection) 100 units/mL, 200 units/mL; and Saxenda® (liraglutide injection) 3 mg.
  • Phase 3 studies for Victoza®, Ozempic®, Xultophy® 100/3.6, Tresiba®, and Saxenda®.

The website is owned and operated by Novo Nordisk and is intended for licensed Health Care Providers only. By clicking “Continue” below, you verify that you are a licensed health care provider and that you agree to the terms and conditions of this tool.

Request this article.

To request a copy of this study from the Medical Information department, please complete the form below. This form is for use by U.S. practicing healthcare providers only.

This site is not to be used to report adverse events or product complaints. To report an adverse event or product complaint, please call 1-800-727-6500.

I am not a Physician 2 or a licensed healthcare professional in MA, VT, or DC.
I approve the receipt of reportable article(s).
Please send ONLY non-reportable information.

This full article is a reportable item. To receive this article, please unselect the “Please send ONLY non-reportable information” radio button from your question form.

This full study is a reportable item. To receive this study, please unselect the “Please send ONLY non-reportable information” radio button from your question form.

Do you treat patients below the age of 18?

Yes
No
1As required by the Sunshine Act, Novo Nordisk will disclose to the Federal government the value of certain educational materials including articles/reprints provided to Physicians and this information may be made publicly available by CMS. Novo Nordisk will also report similar information for healthcare professionals licensed to practice in those states with reporting requirements. 2Sunshine Act defines Physician as a licensed MD, DO, dentist, podiatrist, optometrist, or chiropractor.

Ask a Question.

To request information from the Medical Information department, please complete the form below. This form is for use by U.S. practicing healthcare providers only.

This site is not to be used to report adverse events or product complaints. To report an adverse event or product complaint, please call 1-800-727-6500.

I am not a Physician 2 or a licensed healthcare professional in MA, VT, or DC.
I approve the receipt of reportable article(s).
Please send ONLY non-reportable information.

This full study is a reportable item. To receive this study, please unselect the “Please send ONLY non-reportable information” radio button from your question form.

Do you treat patients below the age of 18?

Yes
No
1As required by the Sunshine Act, Novo Nordisk will disclose to the Federal government the value of certain educational materials including articles/reprints provided to Physicians and this information may be made publicly available by CMS. Novo Nordisk will also report similar information for healthcare professionals licensed to practice in those states with reporting requirements. 2Sunshine Act defines Physician as a licensed MD, DO, dentist, podiatrist, optometrist, or chiropractor.
0
lives studied
0
articles

1. Saxenda ® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of ≥30 kg/m2 (obese) or BMI ≥27 kg/m2 (overweight) in the presence of at least one weight-related co-morbid condition (e.g., hypertension, type 2 diabetes, or dyslipidemia).

2. Health Economics & Outcomes Research

3. Saxenda® is not indicated for treatment of Type 2 Diabetes.

4. Victoza®, Ozempic®, Xultophy® 100/3.6 and Tresiba® are not indicated for chronic weight management.

Return to novonordiskmedical.com

Sort our evidence library by evidence type, product and category. Select your areas of interest, view your results.
View Articles

Articles (0)

  • Prescribing Information Study
  • Real World Evidence
  • Health Economic Data
See additional information on PubMed